RARE Ultragenyx Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RARE

Price (delayed)

$25.83

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.83

Enterprise value

$3.62B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 24

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of ...

Highlights
The revenue rose by 18% year-on-year and by 7% since the previous quarter
The company's gross profit rose by 15% YoY and by 6% QoQ
Ultragenyx Pharmaceutical's net income has decreased by 10% YoY but it has increased by 3.8% QoQ
RARE's EPS is down by 6% year-on-year but it is up by 4.4% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 36% YoY
The quick ratio has decreased by 33% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ultragenyx.com
Peers: BMRN LXRX

Key stats

What are the main financial stats of RARE

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
2.01%
1 week
-2.49%
1 month
-9.75%
1 year
-12.5%
YTD
12.3%
QTD
-22.64%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$717.21M
Gross profit
$595.88M
Operating income
-$528.17M
Net income
-$585.97M
Gross margin
83.1%
Net margin
-81.7%
The revenue rose by 18% year-on-year and by 7% since the previous quarter
The company's gross profit rose by 15% YoY and by 6% QoQ
The company's operating margin rose by 12% QoQ and by 11% YoY
Ultragenyx Pharmaceutical's net margin has increased by 10% from the previous quarter and by 6% YoY

Price vs fundamentals

How does RARE's price correlate with its fundamentals

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
N/A
P/S
3.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.05
RARE's EPS is down by 6% year-on-year but it is up by 4.4% since the previous quarter
The equity has declined by 23% since the previous quarter
The P/S is 57% lower than the 5-year quarterly average of 8.5 and 8% lower than the last 4 quarters average of 4.0
The revenue rose by 18% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
The return on assets has declined by 18% year-on-year but it has increased by 2.8% since the previous quarter
RARE's return on sales is up by 10% since the previous quarter and by 7% year-on-year
The company's return on invested capital fell by 10% YoY but it rose by 8% QoQ

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 18% less than the total liabilities
The company's total liabilities rose by 35% YoY
The quick ratio has decreased by 33% YoY and by 15% QoQ
Ultragenyx Pharmaceutical's debt to equity has plunged by 166% YoY but it has increased by 18% from the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 36% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.